ADSTILADRIN + Ruvidar (TLD-1433)
BCG-unresponsive NMIBC
Development Agreement / Pre-Clinical? (Combination Study)Active
Key Facts
Indication
BCG-unresponsive NMIBC
Phase
Development Agreement / Pre-Clinical? (Combination Study)
Status
Active
Company
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global, private biopharmaceutical company founded in 1950 and headquartered in Saint-Prex, Switzerland, with a significant operational presence in Prague, Czech Republic. The company focuses on high-need therapeutic areas, with a strong commercial portfolio and pipeline in reproductive medicine, uro-oncology, gastroenterology, and orthopaedics. Its recent strategic activities include label expansions for its gene therapy ADSTILADRIN, real-world evidence generation for its microbiome therapeutic REBYOTA, and entering into new clinical collaborations in bladder cancer.
View full company profile